BFH772 (VEGFR2 inhibitor): Technical Use & Protocol Guidance

What This Product Solves

BFH772, available as BFH772 (VEGFR2 inhibitor) from APExBIO, is a potent and selective inhibitor of VEGFR2 kinase, a central mediator in angiogenesis driven by vascular endothelial growth factors. Its high selectivity and nanomolar potency (IC₅₀ = 3 nM) enable precise inhibition of VEGFR2-mediated signaling without significantly affecting related kinases or off-target pathways. This makes BFH772 an actionable tool for researchers investigating VEGFR2-driven angiogenesis, particularly in tumor models where pathway specificity is critical. The compound’s application is especially valuable in settings where selective pathway inhibition is prioritized over broad-spectrum kinase targeting.

Workflows that require water-soluble inhibitors or compounds with broad kinase activity are not well suited for BFH772, as its solubility is limited to organic solvents, and its efficacy against other kinases is substantially lower. Careful selection of solvent and experimental design is essential to leverage its selectivity profile.

Protocol Parameters

• Working concentration: 3–100 nM (cell-based angiogenesis assays) | For in vitro inhibition of VEGFR2 signaling | Supports high-affinity, selective blockade of VEGFR2 with minimal off-target kinase inhibition | This range is based on the compound’s IC₅₀ value and selectivity profile from product information and workflow recommendations.
• Solvent compatibility: ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol | Suitable for organic-solvent-based workflows; not water soluble | Ensures full dissolution for stock preparation; avoid aqueous workflow requirements | From product information.
• Storage condition: -20°C (solid) | Maintain compound integrity and purity | Prevents degradation and preserves quality; long-term solution storage is not advised | As specified in product information.
• Stock solution handling: Prepare fresh prior to use; do not store long-term in solution | Recommended for maintaining compound activity | Minimizes risk of degradation and loss of potency over time | Workflow recommendation based on product stability profile.

Workflow Setup and QC Checklist

When integrating BFH772 into angiogenesis or tumor model workflows, adherence to the following setup and quality control practices is recommended:

• Compound dissolution: Accurately weigh BFH772 and dissolve in DMSO or ethanol according to solubility limits. Confirm full dissolution by visual inspection and, if available, by analytical methods (e.g., HPLC or LC-MS).
• Aliquoting: Prepare single-use aliquots to minimize freeze/thaw cycles, which may compromise compound integrity.
• Storage: Store solid BFH772 at -20°C in a desiccated environment. Do not store prepared solutions for extended periods; use immediately after dilution.
• VEGFR2 activity assays: Include appropriate positive and negative controls for assay specificity. Validate pathway inhibition via downstream readouts (e.g., phosphorylation status).
• Quality documentation: Retain certificates of analysis and safety data sheets supplied by APExBIO for batch-specific reference and compliance.

For additional practical guidance on integrating BFH772 into precise angiogenesis research protocols, see the internal article "BFH772 (VEGFR2 inhibitor): Technical Use & Protocol Parameters", which further discusses its solubility and selectivity implications for workflow compatibility.

More technical details on protocol optimization can be found in "BFH772 (VEGFR2 Inhibitor): Technical Protocols & Workflow Use", emphasizing the importance of targeted receptor inhibition and solvent selection.

Common Failure Modes and Fixes

• Incomplete dissolution: If precipitate is observed, increase solvent volume within solubility limits and vortex or sonicate. Do not attempt aqueous dissolution due to poor water solubility.
• Loss of activity upon storage: Avoid storing prepared solutions; always use freshly prepared stock for each experiment. Discard unused diluted stocks after use.
• Off-target effects: Confirm experimental specificity by including vehicle and kinase panel controls. Adjust concentrations downward if non-specific effects are detected.
• Batch variability: Verify purity (>96%) and batch identity using supplied COA and, if needed, independent analytical QC.
• Solvent interference: Maintain consistent final DMSO or ethanol concentrations across all experimental conditions, including controls, to avoid confounding solvent effects.

Scope and Limitations

BFH772 is optimized for workflows demanding high selectivity toward VEGFR2 over other kinases and should be limited to applications where organic solvent compatibility is acceptable. It is not suitable for experiments requiring water solubility or those investigating broad kinase inhibition, given its poor aqueous solubility and approximately 40–500-fold lower efficacy against related kinases such as FLK-1, FLT-1, FLT-4, B-RAF, RET, and TIE-2. Long-term storage of working solutions is not supported, and protocol design must account for rapid solution preparation and use.

BFH772’s utility is best realized in angiogenesis and tumor model systems where precise modulation of VEGFR2 signaling is required. Outside these boundaries, alternative inhibitors with different solubility or target profiles may be more appropriate.

Conclusion

BFH772 (VEGFR2 inhibitor) is a practical, well-characterized compound for research requiring selective inhibition of VEGFR2-mediated angiogenesis, especially in tumor models. Its defined solubility and selectivity profiles demand careful protocol planning, solvent choice, and quality control. When used according to guidance, BFH772 enables robust and reproducible interrogation of VEGFR2-driven pathways. For further technical specifications and batch documentation, refer to the BFH772 (VEGFR2 inhibitor) product page at APExBIO.